 I know if Sarah receives MDMA or not. I mean, I shouldn't be able to tell. I'm not informed by the study protocol, obviously, right? There's meant to be double blind. I just checked the MAPS website today before the interview, and they still maintain that both trials are double blind. But of course, that's just not the case. Neither clients are blind nor clinicians are blind. And that's just really, really problematic for a clinical trial. It doesn't really allow for valid inferences.